On March 24, 2023 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that the Annual Report for 2022 has been published. Because of environmental and cost reasons, Alligator Bioscience has chosen not to print the annual report (Press release, Alligator Bioscience, MAR 24, 2023, View Source [SID1234629290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Annual Report is attached as a PDF and is available on the company’s website.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00

Marie Svensson, CFO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 03

This information is information that Alligator Bioscience is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-03-24 11:00 CET.